OEM by QIAGEN: Strategic Partnerships – A Partner that Extends Your Capabilities
Exhibitor: QIAGEN N.V.
Date: 2024-06-26
Booth No.: L823
OEM by QIAGEN: Strategic Partnerships – A Partner that Extends Your Capabilities
Bulk Manufacturing Capabilities
As our strategic partners, OEM by QIAGEN offer access to the technologies, products and related capabilities. We offer modified and rebranded components or complete workflows and kits according to your specifications. Kit reagents and components, custom fills or other bulk formats, lyophilization, including a patent and licensing check. We offer customized manufacturing and packaging to match your brand, with global support for direct shipment. We will guide you through a step-by-step OEM process by our experienced project management team and regional sales team in making the right “make or buy” decision to ensure your innovation materializes into a market-ready product.
Quality at Scale
Scalability without compromise on quality, from prototype to bulk manufacturing, we provide you with high-quality OEM solutions at scale. You can be sure of outstanding quality control processes. With our ISO and GMP certified manufacturing facilities and offices located all over the world, we offer global support and commercial excellence.
Global Reach
With manufacturing facilities in multiple locations and offices located all over the world, we ensure a deep understanding of your market. Whether you need our service locally or to utilize our global presence, we can support you with full confidentiality. We can support you worldwide with diverse industry-grade components produced at various locations. Reduce economic or geo-political uncertainties by working with a reliable global manufacturer. You have peace of mind with OEM by QIAGEN.
FAQs:
What are the criteria for outsourcing bulk production?
There are two primary criteria: Rebranding and customization. We cater to B2B business partners (i.e., molecular assay manufacturing companies) who produce and sell their own branded products. Also, companies interested in incorporating QIAGEN technologies seamlessly into their brand or selling a product as part of their IVD assay workflow. Off-the-shelf kits or components can be rebranded and ordered without minimum order quantity (MOQ), while customized products require MOQ depending on the complexity of the product.
Is there an extra licensing cost?
There is no added cost to purchase a license for a particular technology as part of OEM bulk manufacturing. All prices are quoted as a total sum based on your specifications, and are negotiable on a case-to-case basis.
OEM by QIAGEN – Be Our Strategic Partners with Bulk Manufacturing Capabilities and Quality at Scale in Global Processes:
Establish a market position through speed and a collaboration that unleashes the power of molecular biology. With QIAGEN Strategic Partnerships you can conduct your biotechnology manufacturing quickly without compromising compliance, quality or consistency, ensuring that you’re the first to market.
With our track record of kit manufacturing, we turn innovations into commercial products. You can be sure of outstanding quality as we scale to match your business growth. No matter the size of your company, we are committed to supporting you every step of the way. With you as our strategic partners, you can be sure that your OEM outsourced components and products are delivered with consistent quality at scale, with capabilities in bulk manufacturing at diverse manufacturing sites.
If your company has a requirement for a product sourcing and a manufacturing partner that stands above the crowd then let’s connect via email (OEM-sales@qiagen.com).
Promotional video - OEM by QIAGEN: Strategic Partnerships
More Exhibitor's Press Release
- 2024BIO Asia Taiwan. Golden Biotech Seminar Registration GOLDEN BIOTECHNOLOGY CORP. / 2024-06-28
- CRISPR cGMP gRNA Manufacturing MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- High-Throughput NGS Assistant - Feyond-F100 Fluorescence Microplate Reader MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- CLUBIO Life science solutions help universities upgrade equipments MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- EDA providing the most advanced and innovative optoelectronic medical equipment. EDA MEDICAL DEVICES TECHNOLOGY INC. / 2024-06-25
- TaiMed Biologics: Comprehensive CDMO Services from Bench to Market TAIMED BIOLOGICS INC. / 2024-06-25
- Comparison of Maglev Centrifugal Pump and Quaternary Diaphragm Pump Effects on mRNA encapsulated LNP LEVITRONIX GMBH TAIWAN BRANCH / 2024-06-24
- Marker X Decodes the Cancer Proteome Breaking the Limits of Early Cancer Screening Globally! MARKER EXPLORATION CORP. / 2024-06-21
- EffPha is the leading CRO for early phase oncology trials EFFICIENT PHARMA MANAGEMENT CORP. / 2024-06-20
- FUJIFILM Toyama Chemical and Synplogen Enter Strategic Business Alliance Agreement on CDMO Services FUJIFILM CORPORATION / 2024-06-18
- TriLink BioTechnologies® and FUJIFILM Toyama Chemical Sign Non-exclusive License FUJIFILM CORPORATION / 2024-06-18
- BioBunBan is committed to manufacturing top-quality bio-materials BIOBUNBAN CO., LTD. / 2024-06-17
- BioBunBan is committed to manufacturing top-quality bio-materials BIOBUNBAN CO., LTD. / 2024-06-17
- Aggregating Experience, Leading the New Trend in Medical Micro-Molding ANN TONG INDUSTRIAL CO.,LTD / 2024-06-17
- SCIWIN Laboratories Co., Ltd. / Organic Synthesis R&D and Contract Manufacturing Organization SCIWIN LABORATORIES CO., LTD. / 2024-06-15
- INORA Brand Strategy to Drive Revenue Growth INORA PHARMACEUTICAL MACHINERY CO., LTD. / 2024-06-14
- SCI's highest quality static control equipment-------your best choice!! CHAO-DEE SCIENCE CO., LTD. / 2024-06-14
- Fujifilm to Invest $1.2 bn to Expand its Large-Scale Cell Culture CDMO Business in North Carolina FUJIFILM CORPORATION / 2024-06-14
- Diener Plasma equipments and Parylene Coating from Germany are worthy of your confidence and trust. CHAO-DEE SCIENCE CO., LTD. / 2024-06-14
- CSB promotes automated exosome production technology, leading the new trend in regenerative medicine COLD SPRING BIOTECH CORP. / 2024-06-13